|
[1]
|
Yin, Q., Wu, L., Han, L., et al. (2023) Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Review. Frontiers in Immunology, 14, Article 1167975. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Bagchi, S., Yu-an, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology, 16, 223-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Schneider, B.J., Naidoo, J., Santomasso, B.D., et al. (2021) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39, 4073-4126.
|
|
[5]
|
Poto, R., Troiani, T., Criscuolo, G., et al. (2022) Holistic Approach to Immune Checkpoint Inhibi-tor-Related Adverse Events. Frontiers in Immunology, 13, Article 804597. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Barron, C.C., Stefanova, I., Cha, Y., et al. (2023) Chronic Im-mune-Related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review. Journal for Immunotherapy of Cancer, 11, e006500. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Chitnis, S.D. and Mortazavi, A. (2023) Clinical Guideline Highlights for the Hospitalist: Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhib-itor Therapy. Journal of Hospital Medicine, 18, 1013- 1016. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Chang, L.S., Barroso-Sousa, R., Tolaney, S.M., et al. (2019) Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews, 40, 17-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Ferrari, S.M., Fallahi, P., Elia, G., et al. (2019) Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 20, Article 2560. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Iglesias, P. (2018) Cancer Immunotherapy-Induced Endocrinopathies: Clinical Behavior and Therapeutic Approach. European Journal of Internal Medicine, 47, 6-13. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Basek, A., Jakubiak, G.K., Cieślar, G., et al. (2023) Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Ther-apy. Cancers, 15, Article 5786. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Carlino, M.S., Larkin, J. and Long, G.V. (2021) Immune Checkpoint Inhibitors in Melanoma. Lancet (London, England), 398, 1002-1014. [Google Scholar] [CrossRef]
|
|
[13]
|
Willsmore, Z.N., Coumbe, B.G.T., Crescioli, S., et al. (2021) Combined Anti-PD-1 and Anti-CTLA-4 Checkpoint Blockade: Treatment of Melanoma and Immune Mechanisms of Ac-tion. European Journal of Immunology, 51, 544-556. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Marin-Acevedo, J.A., Kimbrough, E.O. and Lou, Y. (2021) Next Gen-eration of Immune Checkpoint Inhibitors and Beyond. Journal of Hematology & Oncology, 14, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Wright, J.J., Powers, A.C. and Johnson, D.B. (2021) Endocrine Toxicities of Immune Checkpoint Inhibitors. Nature Reviews Endocrinology, 17, 389-399. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science (New York, NY), 359, 1350-1355. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Martins, F., Sofiya, L., Sykiotis, G.P., et al. (2019) Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nature Reviews Clinical Oncology, 16, 563-580. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
De Filette, J., Andreescu, C.E., Cools, F., et al. (2019) A System-atic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research, 51, 145-156. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Haanen, J., Obeid, M., Spain, L., et al. (2022) Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 33, 1217-1238. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Tan, M.H., Iyengar, R., Mizokami-Stout, K., et al. (2019) Spec-trum of Immune Checkpoint Inhibitors-Induced Endocrinopathies in Cancer Patients: A Scoping Review of Case Reports. Clinical Diabetes and Endocrinology, 5, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Chera, A., Stancu, A.L. and Bucur, O. (2022) Thyroid-Related Adverse Events Induced by Immune Checkpoint Inhibitors. Fron-tiers in Endocrinology, 13, Article 1010279. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Iwama, S., Koba-yashi, T., Yasuda, Y., et al. (2022) Immune Checkpoint Inhibitor-Related Thyroid Dysfunction. Best Practice & Re-search Clinical Endocrinology & Metabolism, 36, Article 101660. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Lee, H., Hodi, F.S., Giobbie-Hurder, A., et al. (2017) Character-ization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunology Re-search, 5, 1133-1140. [Google Scholar] [CrossRef]
|
|
[24]
|
Okada, N., Iwama, S., Okuji, T., et al. (2020) Anti-Thyroid Antibodies and Thyroid Echo Pattern at Baseline as Risk Factors for Thyroid Dysfunction Induced by Anti-Programmed Cell Death-1 Antibodies: A Prospective Study. British Journal of Cancer, 122, 771-777. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Yasuda, Y., Iwama, S., Sugiyama, D., et al. (2021) CD4+ T Cells Are Essential for the Development of Destructive Thyroiditis Induced by Anti-PD-1 Antibody in Thyroglobu-lin-Immunized Mice. Science Translational Medicine, 13. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Iwama, S., De Remigis, A., Callahan, M.K., et al. (2014) Pitui-tary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Science Translational Medicine, 6, 230ra45. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Angell, T.E., Min, L., Wieczorek, T.J., et al. (2018) Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes & Diseases, 5, 46-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Neppl, C., Kaderli, R.M., Trepp, R., et al. (2018) Histology of Nivolumab-Induced Thyroiditis. Thyroid: Official Journal of the American Thyroid Association, 28, 1727-1728. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Yu, C., Chopra, I.J. and Ha, E. (2015) A Novel Melanoma Therapy Stirs up a Storm: Ipilimumab-Induced Thyrotoxicosis. Endocrinology, Diabetes & Metabolism Case Reports, 2015, Ar-ticle ID: 140092. [Google Scholar] [CrossRef]
|
|
[30]
|
Mcmillen, B., Dhillon, M.S. and Yong-Yow, S. (2016) A Rare Case of Thyroid Storm. BMJ Case Reports, 2016, bcr2016214603. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Khan, U., Rizvi, H., Sano, D., et al. (2017) Nivolumab Induced Myxedema Crisis. Journal for Immunotherapy of Cancer, 5, 13. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Mizukoshi, T., Fukuoka, H. and Takahashi, Y. (2022) Immune Checkpoint Inhibitor-Related Hypophysitis. Best Practice & Research Clinical Endocrinology & Metabolism, 36, Article 101668. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Jessel, S., Weiss, S.A., Austin, M., et al. (2022) Immune Check-point Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers in Oncology, 12, Article 836859. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Faje, A.T., Sullivan, R., Lawrence, D., et al. (2014) Ipili-mumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients with Metastatic Melano-ma. The Journal of Clinical Endocrinology and Metabolism, 99, 4078-4085. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Chalan, P., Thomas, N. and Caturegli, P. (2021) Th17 Cells Contribute to the Pathology of Autoimmune Hypophysitis. Journal of Immunology (Baltimore, MD: 1950), 206, 2536-2543. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Caturegli, P., Di, Dalmazi, G., Lombardi, M., et al. (2016) Hy-pophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. The American Journal of Pathology, 186, 3225- 3235. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Tahir, S.A., Gao, J., Miura, Y., et al. (2019) Autoimmune Anti-bodies Correlate with Immune Checkpoint Therapy- Induced Toxicities. Proceedings of the National Academy of Sciences of the United States of America, 116, 22246- 22251. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Iwama, S. and Arima, H. (2020) Anti-Pituitary Antibodies as a Marker of Autoimmunity in Pituitary Glands. Endocrine Journal, 67, 1077-1083. [Google Scholar] [CrossRef]
|
|
[39]
|
Kanie, K., Iguchi, G., Bando, H., et al. (2021) Mecha-nistic Insights into Immune Checkpoint Inhibitor-Related Hypophysitis: A Form of Paraneoplastic Syndrome. Cancer Immunology, Immunotherapy: CII, 70, 3669-3677. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Elia, G., Ferrari, S.M., Galdiero, M.R., et al. (2020) New Insight in Endocrine-Related Adverse Events Associated to Immune Checkpoint Blockade. Best Practice & Research Clinical Endocrinology & Metabolism, 34, Article 101370. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Faje, A., Reynolds, K., Zubiri, L., et al. (2019) Hypophysitis Secondary to Nivolumab and Pembrolizumab Is a Clinical Entity Distinct from Ipilimumab-Associated Hypophysitis. European Journal of Endocrinology, 181, 211-219. [Google Scholar] [CrossRef]
|
|
[42]
|
Albarel, F., Gaudy, C., Castinetti, F., et al. (2015) Long-Term Fol-low-Up of Ipilimumab-Induced Hypophysitis, A Common Adverse Event of the Anti-CTLA-4 Antibody in Melanoma. European Journal of Endocrinology, 172, 195-204. [Google Scholar] [CrossRef]
|
|
[43]
|
Ryder, M., Callahan, M., Postow, M.A., et al. (2014) Endocrine-Related Adverse Events Following Ipilimumab in Patients with Advanced Melanoma: A Comprehensive Retrospective Review from a Single Institution. Endocrine-Related Cancer, 21, 371-381. [Google Scholar] [CrossRef]
|
|
[44]
|
Castillero, F., Castillo-Fernández, O., Jiménez-Jiménez, G., et al. (2019) Cancer Immunotherapy-Associated Hypophysitis. Future Oncology (London, England), 15, 3159-3169. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Lam, T., Chan, M.M., Sweeting, A.N., et al. (2015) Ipili-mumab-Induced Hypophysitis in Melanoma Patients: An Australian Case Series. Internal Medicine Journal, 45, 1066-1073. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Akturk, H.K., Kahramangil, D., Sarwal, A., et al. (2019) Im-mune Checkpoint Inhibitor-Induced Type 1 Diabetes: A Systematic Review and Meta-Analysis. Diabetic Medicine: A Journal of the British Diabetic Association, 36, 1075- 1081. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Wang, Y., Zhou, S., Yang, F., et al. (2019) Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. JAMA Oncology, 5, 1008-1019. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Cho, Y.K. and Jung, C.H. (2023) Immune-Checkpoint Inhibi-tors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice. Diabetes & Metabolism Journal, 47, 757-766. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Wright, J.J., Salem, J.E., Johnson, D.B., et al. (2018) Increased Re-porting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care, 41, e150-e151. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Lu, J., Yang, J., Liang, Y., et al. (2019) Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. Frontiers in Pharmacology, 10, Ar-ticle 1453. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Ji, H.H., Tang, X.W., Dong, Z., et al. (2019) Adverse Event Pro-files of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Re-ports Submitted to FAERS. Clinical Drug Investigation, 39, 319-330. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Chen, X., Affinati, A.H., Lee, Y., et al. (2022) Immune Check-point Inhibitors and Risk of Type 1 Diabetes. Diabetes Care, 45, 1170-1176. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Roep, B.O., Thomaidou, S., Van, Tienhoven, R., et al. (2021) Type 1 Dia-betes Mellitus as a Disease of the β-Cell (Do Not Blame the Immune System?). Nature Reviews Endocrinology, 17, 150-161. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Osum, K.C., Burrack, A.L., Martinov, T., et al. (2018) Interfer-on-Gamma Drives Programmed Death-Ligand 1 Expression on Islet β Cells to Limit T Cell Function during Autoimmune Diabetes. Scientific Reports, 8, Article No. 8295. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Rui, J., Deng, S., Arazi, A., et al. (2017) β Cells That Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice. Cell Metabolism, 25, 727-738. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Ansari, M.J., Salama, A.D., Chitnis, T., et al. (2003) The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. The Journal of Experimental Medicine, 198, 63-69. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Ding, J.T., Yang, K.P., Lin, K.L., et al. (2022) Mechanisms and Thera-peutic Strategies of Immune Checkpoint Molecules and Regulators in Type 1 Diabetes. Frontiers in Endocrinology, 13, Article 1090842. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Quandt, Z., Young, A. and Anderson, M. (2020) Immune Checkpoint Inhibitor Diabetes Mellitus: A Novel Form of Autoimmune Diabetes. Clinical and Experimental Immunology, 200, 131-140. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Yoneda, S., Imagawa, A., Hosokawa, Y., et al. (2019) T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes after Administration of Immune Checkpoint Inhibitors. Diabetes Care, 42, e116-e118. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Perdigoto, A.L., Deng, S., Du, K.C., et al. (2022) Immune Cells and Their Inflammatory Mediators Modify β Cells and Cause Checkpoint Inhibitor-Induced Diabetes. JCI Insight, 7, e156330. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Clotman, K., Janssens, K., Specenier, P., et al. (2018) Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. The Journal of Clinical Endocrinology and Metabolism, 103, 3144-3154. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Deligiorgi, M.V. and Trafalis, D.T. (2023) A Concerted Vision to Ad-vance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 24, Article 7630. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Lo Preiato, V., Salvagni, S., Ricci, C., et al. (2021) Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: Type 1 Diabetes Variant or New Clinical Entity? Review of the Literature. Reviews in Endocrine & Metabolic Disorders, 22, 337-349. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Yun, K., Daniels, G., Gold, K., et al. (2020) Rapid Onset Type 1 Diabetes with Anti-PD-1 Directed Therapy. Oncotarget, 11, 2740-2746. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Wu, L., Tsang, V.H.M., Sasson, S.C., et al. (2021) Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 12, Article 764138. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Falcao, C.K., Cabral, M.C.S., Mota, J.M., et al. (2019) Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma. The Journal of Clinical Endocrinology and Metabolism, 104, 3245-3248. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Jehl, A., Cugnet-Anceau, C., Vigouroux, C., et al. (2019) Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes. Diabetes Care, 42, 2008-2010. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
Leiter, A., Carroll, E., Brooks, D., et al. (2021) Characterization of Hyper-glycemia in Patients Receiving Immune Checkpoint Inhibitors: Beyond Autoimmune Insulin-Dependent Diabetes. Dia-betes Research and Clinical Practice, 172, Article 108633. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Liu, Y., Zhang, H., Zhou, L., et al. (2021) Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management. Frontiers in Oncology, 11, Article 627612. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Atkinson, M., Lansdown, A J. (2022) Endocrine Immune-Related Adverse Events: Adrenal, Parathyroid, Diabetes Insipidus, and Lipoatrophy. Best Practice & Research Clinical Endocri-nology & Metabolism, 36, Article 101635. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Lu, D., Yao, J., Yuan, G., et al. (2022) Immune Checkpoint In-hibitor-Associated New-Onset Primary Adrenal Insufficiency: A Retrospective Analysis Using the FAERS. Journal of Endocrinological Investigation, 45, 2131-2137. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Grouthier, V., Lebrun-Vignes, B., Moey, M., et al. (2020) Im-mune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. The Oncologist, 25, 696-701. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Martella, S., Lucas, M., Porcu, M., et al. (2023) Primary Adrenal Insufficiency Induced by Immune Checkpoint Inhibitors: Biological, Clinical, and Radiological Aspects. Semi-nars in Oncology. [Google Scholar] [CrossRef] [PubMed]
|
|
[74]
|
Simpson, H., Tomlinson, J., Wass, J., et al. (2020) Guid-ance for the Prevention and Emergency Management of Adult Patients with Adrenal Insufficiency. Clinical Medicine (London, England), 20, 371-378. [Google Scholar] [CrossRef] [PubMed]
|
|
[75]
|
Gunawan, F., George, E. and Roberts, A. (2018) Combination Immune Checkpoint Inhibitor Therapy Nivolumab and Ipilimumab Associated with Multiple Endocrinopathies. Endocri-nology, Diabetes & Metabolism Case Reports, 2018, 1-5. [Google Scholar] [CrossRef]
|
|
[76]
|
Brilli, L., Calabrò, L., Campanile, M., et al. (2020) Permanent Diabetes Insipidus in a Patient with Mesothelioma Treated with Im-munotherapy. Archives of Endocrinology and Metabolism, 64, 483-486. [Google Scholar] [CrossRef] [PubMed]
|
|
[77]
|
Yu, M., Liu, L., Shi, P., et al. (2021) Anti-PD-1 Treat-ment-Induced Immediate Central Diabetes Insipidus: A Case Report. Immunotherapy, 13, 1255-1260. [Google Scholar] [CrossRef] [PubMed]
|
|
[78]
|
Fleseriu, M., Hashim, I.A., Karavitaki, N., et al. (2016) Hormonal Re-placement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical En-docrinology and Metabolism, 101, 3888-3921. [Google Scholar] [CrossRef] [PubMed]
|
|
[79]
|
Lupi, I., Brancatella, A., Cetani, F., et al. (2020) Activating Antibodies to the Calcium-Sensing Receptor in Immunotherapy-Induced Hypoparathyroidism. The Journal of Clinical Endocrinology and Metabolism, 105, 1581-1588. [Google Scholar] [CrossRef] [PubMed]
|
|
[80]
|
Piranavan, P., Li, Y., Brown, E., et al. (2019) Immune Checkpoint In-hibitor-Induced Hypoparathyroidism Associated with Calcium-Sensing Receptor-Activating Autoantibodies. The Journal of Clinical Endocrinology and Metabolism, 104, 550-556. [Google Scholar] [CrossRef] [PubMed]
|
|
[81]
|
Trinh, B., Sanchez, G.O., Herzig, P., et al. (2019) Inflammation-Induced Hypoparathyroidism Triggered by Combination Immune Checkpoint Blockade for Melanoma. Journal for Immunotherapy of Cancer, 7, 52. [Google Scholar] [CrossRef] [PubMed]
|
|
[82]
|
Bollerslev, J., Rejnmark, L., Marcocci, C., et al. (2015) European Society of Endocrinology Clinical Guideline: Treatment of Chronic Hypoparathyroidism in Adults. European Journal of Endocrinology, 173, G1-G20. [Google Scholar] [CrossRef]
|
|
[83]
|
Gnanendran, S.S., Miller, J.A., Archer, C.A., et al. (2020) Acquired Lipodystrophy Associated with Immune Checkpoint Inhibitors. Melanoma Research, 30, 599-602. [Google Scholar] [CrossRef]
|
|
[84]
|
Haddad, N., Vidal-Trecan, T., Baroudjian, B., et al. (2020) Acquired Generalized Lipodystrophy under Immune Checkpoint Inhibition. The British Journal of Dermatology, 182, 477-480. [Google Scholar] [CrossRef] [PubMed]
|
|
[85]
|
Lupu, J., Pages, C., Laly, P., et al. (2017) Transient Pituitary ACTH-Dependent Cushing Syndrome Caused by an Immune Checkpoint Inhibitor Combination. Melanoma Research, 27, 649-652. [Google Scholar] [CrossRef]
|
|
[86]
|
Shi, Y., Shen, M., Zheng, X., et al. (2020) ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. The Journal of Clinical Endocrinology and Metabolism, 105, e4208-e4218. [Google Scholar] [CrossRef] [PubMed]
|
|
[87]
|
Zhao, Z., Wang, X., Bao, X.Q., et al. (2021) Autoimmune Polyendo-crine Syndrome Induced by Immune Checkpoint Inhibitors: A Systematic Review. Cancer Immunology, Immunotherapy: CII, 70, 1527-1540. [Google Scholar] [CrossRef] [PubMed]
|
|
[88]
|
Kobayashi, T., Iwama, S., Yasuda, Y., et al. (2018) Patients with Antithyroid Antibodies Are Prone to Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. Journal of the Endocrine Society, 2, 241-251. [Google Scholar] [CrossRef] [PubMed]
|
|
[89]
|
Zhou, X., Iwama, S., Kobayashi, T., et al. (2023) Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline. The Journal of Clinical Endocrinology and Metabolism, 108, e1056-e1062. [Google Scholar] [CrossRef] [PubMed]
|
|
[90]
|
Kobayashi, T., Iwama, S., Yamagami, A., et al. (2022) Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade. The Journal of Clinical Endocrinology and Metabolism, 107, e4115-e4123. [Google Scholar] [CrossRef] [PubMed]
|
|
[91]
|
Osorio, J.C., Ni, A., Chaft, J.E., et al. (2017) Antibody-Mediated Thyroid Dysfunction during T-Cell Checkpoint Blockade in Patients with Non-Small-Cell Lung Cancer. Annals of On-cology: Official Journal of the European Society for Medical Oncology, 28, 583-589. [Google Scholar] [CrossRef] [PubMed]
|
|
[92]
|
Kobayashi, T., Iwama, S., Yasuda, Y., et al. (2020) Pituitary Dys-function Induced by Immune Checkpoint Inhibitors Is Associated with Better Overall Survival in Both Malignant Mela-noma and Non-Small Cell Lung Carcinoma: A Prospective Study. Journal for Immunotherapy of Cancer, 8, e000779. [Google Scholar] [CrossRef] [PubMed]
|